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The clinicalKlebsiella pneumoniae INSRA6884 strain exhibited nonsusceptibility to all penicillins tested (MICs of 64 to>2,048
g/ml). TheMICs of penicillins were weakly reduced by clavulanate (from 2,048 to 512g/ml), and tazobactam restored pipera-
cillin susceptibility. Molecular characterization identified the genes blaGES-7 and a new-lactamase gene, blaSHV-107, which en-
coded an enzyme that differed from SHV-1 by the amino acid substitutions Leu35Gln and Thr235Ala. The SHV-107-producing
Escherichia coli strain exhibited only a-lactam resistance phenotype with respect to amoxicillin, ticarcillin, and amoxicillin-
clavulanate combination. The kinetic parameters of the purified SHV-107 enzyme revealed a high affinity for penicillins. How-
ever, catalytic efficiency for these antibiotics was lower for SHV-107 than for SHV-1. No hydrolysis was detected against
oxyimino--lactams. The 50% inhibitory concentration (IC50) for clavulanic acid was 9-fold higher for SHV-107 than for SHV-1,
but the inhibitory effects of tazobactam were unchanged. Molecular dynamics simulation suggested that the Thr235Ala substitu-
tion affects the accommodation of clavulanate in the binding site and therefore its inhibitory activity.
-Lactamases are the most important mechanism of -lactamdrug resistance in Gram-negative bacteria. They hydrolyze
and inactivate -lactams and are divided into four major classes
(A to D) on the basis of their sequence (1). Class B is composed of
metalloenzymes which require the presence of zinc cations for
activity; classes A, C, and D are hydrolases with an active-site ser-
ine (1, 5). Class A enzymes comprise several enzyme families, in-
cluding the clinically relevant -lactamases TEM-1 and SHV-1
(35). These enzymes confer resistance to penicillins and to nar-
row-spectrum cephalosporins but are inhibited by -lactamase
inhibitors such as clavulanate, which have been developed to
evade the activity of these -lactamases (17, 38).
However, the broad-spectrum -lactamases TEM-1, TEM-2,
and SHV-1 have acquired point mutations in key positions, often
near the active site, that have given rise to (i) TEM/SHV-type
extended-spectrum -lactamases (ESBLs), which hydrolyze oxy-
imino--lactams; (ii) TEM/SHV-type inhibitor-resistant -lac-
tamases; and (iii) complex mutant TEMs (CMTs), which can
combine resistance to -lactam inhibitors and activity against
oxyimino--lactams (4, 11, 12, 23, 34). In addition, many recent
reports have described the emergence of class A ESBLs belonging
to other families, such as GES, VEB, PER, and the worldwide-
disseminated CTX-M family (2, 21). The GES family, specifically,
GES-1, has also been reported in many areas including Portugal
(28).
Since 1992, about 35 inhibitor-resistant TEMs (IRTs) and 11
CMTs have been found (http://www.lahey.org/Studies/). How-
ever, only six inhibitor-resistant SHVs (IRSs) have been detected
clinically so far, mainly in Klebsiella pneumoniae strains, in differ-
ent countries (8, 13, 14, 26, 31, 37) (Table 1). No complex mutant
SHV has been encountered, which is surprising since SHV en-
zymes are usually more susceptible to inactivation by clavulanate
than TEM, due to differences in the enzyme active sites (4, 11). In
the SHV family, naturally occurring inhibitor-resistant pheno-
types harbor substitutions at positions Met69 (SHV-49), Ser130
(SHV-10), Arg187 (SHV-26), and Lys234 (SHV-56, SHV-72, and
SHV-84) (numbering according to the Ambler classification) (1,
11) (Table 1). Further investigations of most enzymes and the
corresponding substitutions have been performed. However, the
recently reported enzyme SHV-107 (AM941848) (28), which is
suspected to belong to the IRS group, has not been characterized.
In this study, we report in a clinical K. pneumoniae strain the
coexpression of the ESBL GES-7 and a new IRS-type enzyme
called SHV-107, which, compared to SHV-1, harbors the substi-
tutions Leu35Gln and Thr235Ala. The kinetic constants of SHV-
107 were determined, andmolecular modeling was undertaken to
investigate the role of Thr235Ala in the resistance to clavulanate.
MATERIALS AND METHODS
Bacterial strains and plasmid.K. pneumoniae INSRA6884was isolated in
2006 from the sputum of a 92-year-old woman in an internal medicine
service at the Centro Hospitalar in Coimbra, Portugal (28). The Esche-
richia coliDH5ampC strain and E. coliBL21(DE3) were used for initial
cloning experiments and overexpression of the -lactamase-encoding
gene, respectively. E. coli C600 was used for mating-out assays. Plasmid
pBK-CMV (Stratagene, Amsterdam, TheNetherlands) was used for clon-
ing experiments (9).
Antimicrobial susceptibility testing and ESBL detection.An agar di-
lution method and criteria according to the French Society of Microbiol-
ogy (SFM) (7) were used to determine theMICs of the antibiotics listed in
Table 2.
Analytical IEF. -Lactamases were characterized by isoelectric focus-
ing (IEF) as previously described (6), with strains E. coli C600 (SHV-1, pI
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7.6),K. pneumoniae INSRA5767 (TEM-24, pI 6.5, and SHV-1, pI 7.6), and
E. coli INSRA7813 (GES-1, pI 5.8) as standards.
DNA amplification and sequencing of -lactamase genes. -Lactamase
genes blaSHV, blaOXA, blaTEM, blaCTX, and blaGES were detected by PCR am-
plification and then purified and sequenced as previously described (28).
blaGES-7 gene transfer.Direct transfer of the -lactam resistance phe-
notype and selection of transconjugants were performed as described pre-
viously (29).
Cloning. The blaSHV-107 gene was cloned in the plasmid pBK-CMV
and transferred as previously described (31). The recombinant pBK-
SHV-107 plasmid was transformed by electroporation into the E. coli
BL21(DE3) strain. Transformants were selected with 30 g/ml of kana-
mycin and 50 g/ml of amoxicillin. The orientation of the inserted genes
was confirmed as described elsewhere (31).
Purification of -lactamase. SHV-107 was produced from E. coli
BL21(DE3) in LB broth, supplemented with 30 g/ml kanamycin, 16
TABLE 1 Comparison of amino acid substitutions, inhibitory properties, and epidemiology of IRS -lactamases
-Lactamase
Amino acid at position no.:a
IC50 (M)
(CLA/TAZ)b Strainc Country (yr)d Reference(s)8 35 54 69 130 140 146 187 192 193 234 235 238 240
SHV-1 I L G M S A A A K L K T G E 0.17/0.11 K. pneumoniae Switzerland (1972) 36
SHV-10 Del G R N V S K 6.9/1.3 E. coli Greece (1997) 37
SHV-26 T 0.48/NDe K. pneumoniae Taiwan (2001) 8
SHV-49 I 1.5/2.5 K. pneumoniae France (2004) 13
SHV-56 Q R 2.5/0.75 K. pneumoniae France (2008) 14
SHV-72 F V R 1.72/0.08 K. pneumoniae Portugal (2008) 31
SHV-84 R 2.21/0.03 E. coli Portugal (2010) 26
SHV-107 Q A 1.53/0.11 K. pneumoniae Portugal (2009) 28; this study
a Numbering according to Ambler et al. (1).
b Values of clavulanate (CLA) and tazobactam (TAZ) for the different IRS -lactamases. SHV-1, SHV-72, and SHV-84, SHV-10, and SHV-107 values were determined using 200
M ticarcillin, 50 mM nitrocefin, and 200 M penicillin, respectively, which were incubated with the inhibitor for 5 min at 37°C at pH 7; SHV-49 and SHV-56 values were
determined by benzylpenicillin (100 M) hydrolysis after 3 min of preincubation at 30°C; and SHV-26 values were determined after 10 min of preincubation of nitrocefin with the
clavulanate at room temperature. IC50, 50% inhibitory concentration.
c Strain producing IRS -lactamase, in the first report.
d Country that first reported the -lactamase, and year (in parentheses).
e ND, not determined.
TABLE 2MICs of -lactam antibiotics for the K. pneumoniae clinical strain producing the SHV-107 enzyme, recipient, and transformanta
Antimicrobial drug








(pBK-SHV-107) E. coli C600
E. coli C600
(GES-7)
Amoxicillin 2,048 2 256 2 256
Amoxicillin CLAb 512 2 64 2 8
Ticarcillin 2,048 2 128 2 2,048
Piperacillin 64 1 8 0.5 4
Piperacillin TAZc 4 1 1 0.5 0.5
Amdinocillin 1 0.015 0.015 0.015 0.25
Cephalothin 128 1 1 4 32
Cefuroxime 64 0.5 1 2 16
Cefoperazone 8 0.25 0.25 0.25 0.5
Ceftazidime 128 0.06 0.06 0.06 32
Ceftazidime CLA 8 0.03 0.03 0.015 0.5
Ceftriaxone 4 0.015 0.015 0.015 0.5
Ceftriaxone CLA 0.5 0.015 0.015 0.015 0.015
Cefotaxime 4 0.015 0.015 0.03 0.5
Cefotaxime CLA 0.25 0.015 0.015 0.015 0.03
Aztreonam 2 0.015 0.015 0.06 1
Aztreonam CLA 0.125 0.015 0.015 0.03 0.03
Cefepime 0.25 0.015 0.015 0.015 0.06
Cefoxitin 4 2 2 2 2
Imipenem 0.25 0.25 0.25 0.06 0.06
Kanamycin 4 0.125 0.125 0.125 0.125
Nalidixic acid 4 0.003 0.003 4 4
Ciprofloxacin 0.03 0.003 0.003 0.007 0.007
Trimethoprim 0.5 0.125 0.125 0.125 0.125
a E. coli BL21(DE3)(pBK-SHV-107) and E. coli C600 (GES-7) were a transformant and conjugant, respectively, of K. pneumoniae INSRA6884 (harboring SHV-107 plus GES-7
enzyme).
b CLA, clavulanate at a fixed concentration of 2 g/ml.
c TAZ, tazobactam at a fixed concentration of 4 g/ml.
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g/ml ticarcillin, and 0.1 mM IPTG (isopropyl--D-thiogalactopyrano-
side; Sigma Chemical Co., St. Louis, MO), overnight at 30°C. The enzyme
was extracted by ultrasonic treatment, and the clarified supernatant was
purified as described elsewhere (3, 31).
Determination of-lactamase kinetic constants.TheMichaelis con-
stant (Km) and catalytic activity (kcat) of SHV-107 and the concentrations
of the inhibitors (clavulanate and tazobactam) required to inhibit enzyme
activity by 50% (IC50s) were determined as previously described (3, 31).
Specific activity and IC50s were monitored with penicillin G (200 M) as
the reporter substrate. The inhibitor kinetics with clavulanate were deter-
mined under steady-state conditions for SHV-1 and SHV-107 as previ-
ously described (18, 27). The enzyme activity was monitored with a UV-
1800 spectrophotometer (Shimadzu, Champs sur Marne, France) in
phosphate-buffered saline (PBS) 20 mM (pH 7.4) at 25°C by using 100
M chromogenic substrate nitrocephin (, 17,400 M1 cm1 at 482
nm) (Sigma-Aldrich, France) as the reporter substrate. The kinetic con-
stants were determined three times for each subtract tested.
Molecular modeling. The structural model of SHV-107 was con-
structed from the crystal structure of SHV-1 using Chimera (24). Molec-
ular dynamics simulations (MDSs) were performed as previously de-
scribed with GROMACS software package, version 4.0 (40), using the
parameters of the OPLSAA force field (22) in a periodic cubic box, as
previously described (10). The AutoDock 4.0 package was used to per-
formmolecular docking (33). Coordinates for clavulanate structure were
obtained using CACTVS (http://www2.ccc.uni-erlangen.de/software
/cactvs/) and the CORINA server (19). Structure optimization was calcu-
lated at the 6-31G** level using the Gamess quantum chemistry software
(39). All the torsion angles in clavulanate were set free to perform flexible
docking, and the Gasteiger-Hückel atomic charge was assigned. Kollman
united atompartial chargeswere assigned for the receptor, whichwas kept
rigid during the docking study. Water molecules, ions, and ligands were
removed, except the catalytic water molecule. The empirical free-energy
function and Lamarckian genetic algorithm were used for docking with
the following settings: a maximum number of 25,000,000 energy evalua-
tions, an initial population of 150 randomly placed individuals, a maxi-
mum number of 27,000 generations, a mutation rate of 0.02, a crossover
rate of 0.80, and an elitism value (number of top individuals that auto-
matically survive) of 1. For the local search, the Solis and Wets algo-
rithm was used with a maximum of 300 iterations per search; 100
independent docking runs were performed for each docking experi-
ment. Results were clustered according to default root mean square
deviation (RMSD) criteria.
RESULTS AND DISCUSSION
General characteristics of K. pneumoniae INSRA6884. In this
study, we characterized a clinical K. pneumoniae strain isolated in
a Portuguese hospital coexpressing two different -lactamases,
the IRS enzyme SHV-107 and the ESBL GES-7, of pIs 7.5 and 6.9,
respectively.
Phenotypic characterization.The transconjugant E. coliC600
(GES-7) acquired resistance only to amoxicillin, ticarcillin, ceph-
alothin, cefuroxime, and ceftazidime, in contrast to the clinical
strain, which was resistant to all penicillins and all cephalosporins
tested except cefepime and cefoxitin (Table 2). The addition of
clavulanate drastically reduced the MIC value of oxyimino-
cephalosporins and aztreonam in both the transconjugant and the
clinical strains. Like the clinical strain, E. coli BL21(DE3)(pBK-
SHV-107) acquired resistance to amoxicillin and ticarcillin and
exhibited a synergy of amoxicillin and piperacillin in combination
with clavulanate (2-fold) and tazobactam (8-fold), respectively
(Table 2).
-lactamase analysis. We report for the first time the GES-7
-lactamase isolated in Portugal. Although not associated with
class 1 integrons (data not shown), the gene encoding this
-lactamase was present in a conjugative plasmid. The deduced
amino sequence of blaGES-7 differed from that of GES-1 (1) by
Glu107Lys and Leu125Ala substitutions (Ambler numbering).
SHV-107 enzyme, an IRS -lactamase (IC50 1 M), is the sev-
enth member of this subgroup, which is characterized by the ex-
pression of resistance to clavulanate (Table 1). This enzyme dif-
fered from SHV-1 by the amino acid substitutions Leu35Gln and
Thr235Ala (Table 1) (28). The first substitution, Leu35Gln, fre-
quently encountered and observed alone in the SHV-11 enzyme
(30), is known to have no significant impact on kinetic constants
(32). To our best knowledge, the second substitution is the first
natural substitution reported at position 235 in class A enzymes
(Table 1). In these enzymes, Thr235 residue is part of a conserved
element (Lys234-Ser/Thr235-Gly236). It is situated on the 3
strand of a -sheet in the / domain and forms a major wall of
the catalytic cavity site (10). The hydroxyl function of Ser/Thr-235
contributes to the binding of the conserved C3/C4 carboxylate
function of -lactams (41).
Enzymatic parameters and properties of -lactamase SHV-
107. After purification by ion exchange and gel filtration, the pu-
rity of -lactamase SHV-107 was estimated to be 98% on a
sodium dodecyl sulfate-polyacrylamide gel. The band of 28.8 kDa
corresponds to the molecular mass deduced from the amino acid
sequence (data not shown).
TABLE 3 Comparative kinetic parameters for SHV-1 and SHV-107 -lactamases
Antibiotic
Kinetic parameters of enzyme
SHV-1b SHV-107c
Km (M)a kcat (s1)a
kcat/Km
(M1 · s1) Km (M)a kcat (s1)a
kcat/Km
(M1 · s1)
Penicillin G 23 0.4 1,937 82 84 11 0.9 378 6 34
Amoxicillin 31 1 1,044 10 34 42 4 657 10 16
Ticarcillin 11 3 220 49 20 23 12 51 7 2
Piperacillin 24 0.5 1,490 96 62 31 0.4 412 87 13
Cephalothin 40 1 128 33 3 179 9 0.1 0.001
Ceftazidime 142 3 0.1 NDd ND 0.1 ND
Cefotaxime 257 21 0.1 ND ND 0.1 ND
a Values are means standard deviations.
b The kinetic constants for SHV-1 are from reference 31.
c E. coli BL21(DE3)(pBK-SHV-107) was the transformant producing SHV-107.
d ND, not determinable, because the hydrolysis rates were too low.
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We observed that the substitution Thr235Ala altered SHV-107
kinetic constants against -lactams without dramatic effects on
the resistance to penicillins. Two-fold changes or less between the
SHV-1 and SHV-107 -lactamases were obtained for Km values
for penicillins (11 to 31Mand 11 to 42M, respectively) (Table
3). Catalytic efficiency against penicillins was 2- to 9-fold lower for
SHV-107 (kcat/Km, 2.2 to 34.4 M1 · s1) than for SHV-1 (kcat/
Km, 20.0 to 84.2 M1 · s1) (Table 3). Amoxicillin, with a kcat
value of 657 s1, was the best substrate for SHV-107. Likewise,
previous enzymatic studies of TEM-1 and its isogenic mutant
Ser235Ala showed similar results for penicillins, although themu-
tant had greatly reduced cephalosporinase activity (15, 20). In the
SHV -lactamase family, residue Thr235 is also critical for cepha-
losporinase activity, because its replacement by Ala235 in SHV-
107 leads to severe impairment of the catalytic constant against
cephalosporins, as observed in TEM-type enzyme (15, 20). Km
values were 4-fold higher for cephalothin or not determinable for
the other cephalosporins, because the hydrolysis rate was too low.
It is noteworthy that amoxicillin, ticarcillin, and piperacillin
have similar kinetic parameters, but production of SHV-107
-lactamase increases the MIC by factors of 128, 64, and 8,
respectively. In contrast, Ala235 residue, although it contributes
to a loss of activity, seems to have no influence in the MIC of
cephalothin. These discrepancies between phenotypic and bio-
chemical values could result from the fact that the MIC of a
-lactam for -lactamase-producing bacteria correlates not only
the catalytic efficiency of the enzyme but also its concentration in
the periplasm and the penetration of the antibiotic through the
outer membrane, as noted before (25).
IC50 results showed that tazobactam was 14-fold more active
than clavulanate against the SHV-107 enzyme, as it has a triazole
group at the C2 -methyl position, which led to the improvement
of IC50s (11) (Table 1). IC50s of clavulanate were 9-fold higher for
SHV-107 than for SHV-1, and no loss of sensitivity to tazobactam
was observed. The Thr235Ala substitution affected the suscepti-
bility to clavulanate and consequently the susceptibility to the
combination of amoxicillin-clavulanate. Similarly, three IRS en-
zymes, SHV-56, SHV-72, and SHV-84, which presented an amino
acid substitution in the vicinity of position 235, showed decreased
susceptibility to clavulanate (14, 26, 31).Molecular dynamics sim-
ulations suggested that the Lys234Arg substitution observed in
this mutant probably affects the positioning of the Ser130 side
chain, a key element in the inhibition reactionmediated by clavu-
lanate (31).
SHV-1 and SHV-107 inhibitor kinetics with clavulanate were
further investigated (Table 4).Ki for clavulanate was almost 9-fold
higher for SHV-107 than for SHV-1 (1.82 M versus 0.21 M).
kinact (inactivation constant) and kcat values were closely similar
for both enzymes. Consequently, the second-order rate constants,
kinact/Ki and kcat/Ki, were 10-fold lower for SHV-107 than for
SHV-1, because of the increase in Ki.
Molecular modeling. We investigated the recognition of cla-
vulanate by the SHV-107 binding site using molecular modeling
tools to explain the role of the Thr235Ala substitution in resis-
tance against clavulanate. The introduction of the Thr235Ala sub-
stitution caused no overall or large-scale deviation of dynamic
properties. Likewise, the survey of residues and water molecules
located in the vicinity of position 235 revealed no dramatic change
in this area (data not shown). For SHV-1, all docking experiments
provided a similar conformation and positioning of clavulanate in
the catalytic pocket (RMSD value for clavulanate atoms of1 Å).
The oxygen atom of the -lactam carbonyl function was at a hy-
drogen bond distance of the Ser70 and Ala237 N atoms (2.9 and
2.8 Å, respectively), which form the oxyanion hole. The C3 car-
boxylate function of clavulanate established electrostatic interac-
tion with Ser130 and Thr235 (2.7 to 2.9 Å). For SHV-107, 98% of
clavulanate-docking experiments provided similar positionings of
clavulanate in the SHV-107 catalytic pocket (RMSD value for cla-
vulanate atoms of1 Å). However, the positioning of clavulanate
in SHV-107 was clearly different from that in SHV-1. Clavulanate
was flipped (Fig. 1). Consequently, the oxygen atom of the
-lactam carbonyl function did not interact with the oxyanion
hole. Instead, Ser70 and Ala237 N atoms and the Ala237 O atom
shared hydrogen bonds with the C2 substituent of clavulanate (2.8
to 3.0 Å), and the-lactam ringwas accommodated in the vicinity
of position 244. It emerges from these results that Thr235 favors
the interaction of -lactam carbonyl function with the oxyanion
hole. This interaction is a key factor in active serine acylation by
clavulanate and therefore in the inhibition process mediated by
this inhibitor. The Thr235Ala substitution may therefore affect
the correct orientation of clavulanate in the binding site and con-
sequently the inhibitory activity of clavulanate. This possibility is
supported by the increase in clavulanate Ki with SHV-107.
Conclusion. Our findings show that mutations at Thr235 of
the SHV-1 -lactamase contribute to decreased susceptibility to
-lactamase inhibitors. Given the increasing number of new en-
zymes conferring resistance to -lactamase inhibitors, further in-
vestigations should be undertaken on IRS enzymes. This emer-
TABLE 4 Clavulanate kinetic parameters of SHV-1 and SHV-107 -lactamases
-Lactamase Ki (M)a kinact (s1)a
kinact/Ki
(M1 · s1) kcat (s1)a
kcat/Ki
(M1 · s1) kcat/kinact
SHV-1 0.21 0.06 0.050 0.007 0.23 0.94 0.13 4.48 19
SHV-107 1.82 0.17 0.042 0.009 0.02 0.75 0.11 0.41 18
a Values are means standard deviations.
FIG 1 Clavulanate positioning in SHV-1 (A) and SHV-107 (B) binding sites
after docking experiments usingAutoDock. Carbon atoms are in yellow for the
protein or in green for clavulanate; oxygen atoms are red and nitrogen atoms
blue. Hydrogen bonds are indicated by dashed lines.
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gencemay be the consequence of the widespread use of penicillins
with -lactamase inhibitors (J01CR) in different European coun-
tries, a practice that needs to be reassessed and modified (16).
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